Zoetis Inc. (NYSE:ZTS) EVP Sells $55,804.68 in Stock

Zoetis Inc. (NYSE:ZTS) EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the sale, the executive vice president now owns 16,107 shares in the company, valued at $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

Zoetis Stock Up 1.5 %

ZTS stock traded up $2.56 during midday trading on Tuesday, hitting $174.47. The company’s stock had a trading volume of 2,309,359 shares, compared to its average volume of 2,620,784. The firm’s 50-day moving average is $169.16 and its 200-day moving average is $179.15. The company has a market cap of $78.71 billion, a PE ratio of 32.80, a P/E/G ratio of 2.77 and a beta of 0.90. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $200.53.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be issued a dividend of $0.50 per share. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.15%. Zoetis’s payout ratio is 37.59%.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on ZTS. Morgan Stanley decreased their target price on Zoetis from $248.00 to $243.00 and set an “overweight” rating for the company in a research report on Wednesday, January 29th. UBS Group initiated coverage on Zoetis in a research note on Monday, December 9th. They set a “neutral” rating and a $196.00 price target for the company. Leerink Partnrs raised Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. Leerink Partners initiated coverage on Zoetis in a research report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target for the company. Finally, Piper Sandler reduced their target price on Zoetis from $210.00 to $200.00 and set an “overweight” rating on the stock in a report on Monday. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and an average price target of $214.00.

Hedge Funds Weigh In On Zoetis

Institutional investors have recently bought and sold shares of the stock. Modern Wealth Management LLC increased its stake in Zoetis by 5.8% in the 4th quarter. Modern Wealth Management LLC now owns 12,536 shares of the company’s stock worth $2,155,000 after buying an additional 685 shares in the last quarter. ICW Investment Advisors LLC raised its stake in shares of Zoetis by 22.6% during the fourth quarter. ICW Investment Advisors LLC now owns 4,989 shares of the company’s stock valued at $813,000 after acquiring an additional 920 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Zoetis by 0.3% during the fourth quarter. Vanguard Group Inc. now owns 41,366,877 shares of the company’s stock valued at $6,739,905,000 after acquiring an additional 120,158 shares in the last quarter. Napatree Capital LLC raised its stake in shares of Zoetis by 15.2% during the fourth quarter. Napatree Capital LLC now owns 3,123 shares of the company’s stock valued at $509,000 after acquiring an additional 411 shares in the last quarter. Finally, Stevens Capital Management LP purchased a new position in Zoetis during the fourth quarter valued at approximately $548,000. 92.80% of the stock is owned by institutional investors.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.